Scenesse afamelanotide: Phase II started

Clinuvel announced the start of a physician-led, open-label, Italian Phase II trial to evaluate 16 mg Scenesse implants every 28 days for 12 months in about 10 patients with HHD (also known as familial benign pemphigus). HHD is a rare inherited skin disorder characterized by periodic eruption of plaque-like lesions and blisters on areas where skin folds. ...